Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
